MLLT3 and acute myeloid leukemia: Regarding KMT2A-r AML, the prognostic impact in ELN guidelines [6, 7] is stratified according to the fusion partner with KMT2A::MLLT3 indicating intermediate risk and other KMT2A-r indicating adverse risk.